If you are still having problems viewing this message, please click here for additional help.

Nature Reviews Drug Discovery
TABLE OF CONTENTS

August 2018 Volume 17, Issue 8

Comment
News and Analysis
Research Highlights
Perspectives
Reviews
Correspondence
 
Advertisement


FREE CASE STUDY:
How Top Biotech & Pharma Companies Manage Their Scientific Data

Are you a scientist? If so, get this free white paper to learn how fast growing companies like viDA Therapeutics are managing their scientific data more effectively and more securely. 

Click here to get white paper. 

 

Advertisement
Expand Your Drug Discovery Pipeline – Targeting Cell Metabolism

Discover novel drug targets for oncology, neurodegeneration, diabetes & cardiovascular disease by targeting energy metabolism. Begin your search for cell metabolism targets arranged by disease indication & build your pipeline now!

Download the guide book to advance your target identification studies.
 
Advertisement

BIOPHARMA DEALMAKERS
BIOPHARMA DEALMAKERSCompany Profiles and Partnering Opportunities

 
Advertisement
2018 longlist - see the full line up

The nominations for the 2018 Nature Research Awards for Inspiring Science and Innovating Science are in.

See who's been long listed here >

In partnership with The Estée Lauder Companies.
 

Advertisement
Professor Mark Ferguson, Director-General of Science Foundation Ireland explains why he's looking to attract researchers to work in Ireland.

With access to funding from the Irish Government and industry, it's a great time to think about moving. 

Read more. *ad feature 
 

Comment

 

INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology    pp529 - 530
Sean Khozin, Richard Pazdur & Anand Shah
doi:10.1038/nrd.2018.34
Information Exchange and Data Transformation (INFORMED), a multidisciplinary initiative anchored in the FDA Oncology Center of Excellence, is a decentralized science and technology incubator designed to harness the power of big data and advanced analytics to improve disease outcomes.

News and Analysis

 

Constrained peptides' time to shine?    pp531 - 533
Chris Morrison
doi:10.1038/nrd.2018.125
Constrained peptides have long tantalized drug developers with their potential ability to combine the best attributes of antibodies and small molecules. Finally, a handful of constrained peptides are in late-stage clinical trials.

News in Brief

A snapshot of lead-generation strategies    p534
Asher Mullard
doi:10.1038/nrd.2018.129

REVAMPing antibiotic incentives    p534
Asher Mullard
doi:10.1038/nrd.2018.130

FDA approves first marijuana-derived product    p534
Asher Mullard
doi:10.1038/nrd.2018.131

Biobusiness Briefs

Regulatory watch: FDA new drug approvals in Q2 2018    pp536 - 537
Lisa Urquhart
doi:10.1038/nrd.2018.126

An Audience With

Saurabh Saha    pp538 - 539
doi:10.1038/nrd.2018.127
Saurabh Saha, head of Translational Medicine at Bristol-Myers Squibb, discusses how new tools are opening up translational opportunities in immuno-oncology

From the analyst's couch

The haemophilia drug market    pp541 - 542
Kerri Brown & Graeme Green
doi:10.1038/nrd.2018.54
This article discusses the market for therapies for haemophila, which is forecast to change substantially with the recent launch of emicizumab and the potential future approvals of gene therapies and non-factor treatments.

Advertisement
Focus on Autoimmune Disease from Nature Immunology

A series of Reviews specially commissioned by Nature Immunology discuss the genetic, environmental, microbial and cellular factors underpinning autoimmune disease as well as highlight avenues for therapeutic intervention.

Access free online

Produced with support from
Janssen Research & Development
 
 

Research Highlights

 

Anticancer therapy: Metabolic synthetic lethality    p543
M. Teresa Villanueva
doi:10.1038/nrd.2018.123

Metabolic disorders: IDO inhibitors could change tack to treat metabolic disorders    p544
Megan Cully
doi:10.1038/nrd.2018.124

Genetic disorders: PI3K inhibitor reverses overgrowth syndrome    p545
Sarah Crunkhorn
doi:10.1038/nrd.2018.120

In Brief

Cardiovascular disease: Improving cardiomyocyte contractility    p546
Sarah Crunkhorn
doi:10.1038/nrd.2018.117

Cancer: Releasing tumour suppressors    p546
Sarah Crunkhorn
doi:10.1038/nrd.2018.118

Infectious disease: Curbing cholera    p546
Sarah Crunkhorn
doi:10.1038/nrd.2018.119

Autoimmune disease: A human antibody selectively targets regulatory T cells    p546
Grant Otto
doi:10.1038/nrd.2018.122

Drug Discovery
JOBS of the week
Postdoctoral Fellow
University of Texas Health Science Center at San Antonio
Postdoctoral Fellow (f / m) Stem Cell Research
Evotec AG
Research Scientist I, HIV Immunology
Gilead Sciences
Research Assistant in Prof. Rui Fan and Prof. Manolis Tsakiris's Labs, SIST
ShanghaiTech University
Research Fellow (Modeller)
University of Birmingham
More Science jobs from
Drug Discovery
EVENT
International Conference on Pharmaceutical Sciences and Drug Development (IPSDD 2018)
05.11.18
Prague, Czech Republic
More science events from
Advertisement
Nature Reviews Reader Survey

At Nature Reviews we are continually looking for ways to ensure we meet our readers' needs. Your responses to this short survey will give us insight into how our content may be improved.

Get started here.
 
 

Perspectives

 
Opinion

Principles for targeting RNA with drug-like small molecules    pp547 - 558
Katherine Deigan Warner, Christine E. Hajdin & Kevin M. Weeks
doi:10.1038/nrd.2018.93
Recent studies have indicated the potential to develop small-molecule drugs that act on RNA targets, leading to burgeoning interest in the field. This article discusses general principles for discovering small-molecule drugs that target RNA and argues that the overarching challenge is to identify appropriate target structures in disease-causing RNAs that have high information content and, consequently, appropriate ligand-binding pockets.

Reviews

 

The expanding role of prodrugs in contemporary drug design and development    pp559 - 587
Jarkko Rautio, Nicholas A. Meanwell, Li Di & Michael J. Hageman
doi:10.1038/nrd.2018.46
Prodrug strategies can be used to overcome pharmacokinetic and pharmacodynamic issues in many therapeutic agents. Here, Rautio and colleagues discuss which approaches have been most successful, particularly in the past 10 years, and highlight the challenges in incorporating prodrug moieties during drug development.

Targeting the NLRP3 inflammasome in inflammatory diseases    pp588 - 606
Matthew S. J. Mangan, Edward J. Olhava, William R. Roush, H. Martin Seidel, Gary D. Glick et al.
doi:10.1038/nrd.2018.97
The inflammasome is a key integration point for innate immunity. As such, targeting this signalling hub has the potential to be useful in numerous autoimmune and metabolic disorders. In this article, Latz and colleagues discuss the progress that has been made towards targeting the inflammasome, highlighting the therapeutic potential of some of these compounds as well as caveats for their use.

Correspondence

 

Concerns, challenges and promises of high-content analysis of 3D cellular models    p606
Neil Carragher, Filippo Piccinini, Anna Tesei, O. Joseph Trask Jr, Marc Bickle et al.
doi:10.1038/nrd.2018.99

Advertisement
nature.com webcasts

Nature Research Custom presents a webcast on: Molecular imaging reveals ONC201 antitumor efficacy and immune stimulation in cancer models

Date: Wednesday, August 15, 2018

Join our live webcast to learn about the benefits of cell culture, xenograft tissue sections and mouse models coupled with imaging in preclinical immuno-oncology trials.

This webcast has been produced on behalf of the sponsor who retains sole responsibility for content 

Register for FREE 

Sponsored by:
Perkin Elmer
 
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature